Balaxi Pharmaceuticals Share Price
NSE: BALAXI | Pharmaceuticals | Small Cap
Balaxi Pharmaceuticals Annualised Returns
Balaxi Pharmaceuticals Annualised Returns
Balaxi Pharmaceuticals Share Price Today
Balaxi Pharmaceuticals Share Price Today
As of 20 Oct 2026, Balaxi Pharmaceuticals share price is ₹21.8. The stock opened at ₹22.1 and had closed at ₹22.1 the previous day. During today’s trading session, Balaxi Pharmaceuticals share price moved between ₹21.60 and ₹22.34, with an average price for the day of ₹21.97. Over the last 52 weeks, the stock has recorded a low of ₹15.20 and a high of ₹43.85. In terms of performance, Balaxi Pharmaceuticals share price has declined by 17.5% over the past six months and has declined by 47.23% over the last year.
Balaxi Pharmaceuticals Stock Performance
Balaxi Pharmaceuticals Share Price Chart
Balaxi Pharmaceuticals Share Price Chart
Balaxi Pharmaceuticals Company background
Balaxi Pharmaceuticals Limited was initially incorporated in the name of The Anandam Rubber Company Limited on September 28, 1942. The Company changed its name from The Anandam Rubber Company Limited to Balaxi Ventures Limited on August 08, 2017 and further changed to Balaxi Pharmaceuticals Limited in 2021. Initially, the Company was incorporated with the object of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading. The company previously was a investment company, but the company during the financial year 201819 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.e. Mr. Nirej V. Paul, Mr. V. M. Paulose, Dr. Leelamma T. J and Mrs. Jaya Paul) to acquire 1,670,036 Equity Shares representing 54.94% of the paid up share capital of the Company along with the control over the Company, pursuant to which BOPL made an Open Offer under Regulation 3(1) and Regulation 4 of SEBI (SAST) Regulations, 2011. Control and management of the Company was acquired by BOPL on May 04, 2017 and it became the new promoter of Company and their representatives i.e. Mr. Ashish Maheshwari and Mrs. Minoshi Maheshwari became the new Directors of the Company. Simultaneously, erstwhile promoters stepped down as promoters from Company on same day and Mr. Nirej V. Paul and Dr. Leelamma TJ resigned as Managing Director and as Chairperson from the Company, respectively. Under the above said Open Offer, BOPL acquired 3,30,000 equity shares representing 10.86% equity share capital of the Company. On completion of the Open Offer BOPL became the holding and Promoter Company with an aggregate shareholding of 2000036 Equity Shares (ie 65.79%).The main objects of the company were amended to include activities of International wholesale trading in pharmaceutical, food products and builders hardware on August 08, 2018. The Company commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG products from Financial Year 201819.Further, in February 2019, it kickstarted Food Products business by launching a range of biscuits under the brand YAP.The Company expanded its presence by establishing a central distribution warehouse in Guatemala. This expansion helped in strengthening the network and a wider customer base in 2019. In FY 2024, Company started operations in two Latin American Countries, i.e., Honduras and El Salvador and also started operations in the Central African Republic.The Company completed its first formulation facility in Jadcherla, Hyderabad, focused on General Oral Solid Dosage (OSD) forms in 2025.
Balaxi Pharmaceuticals Financial Highlights
For Q1 FY2026–2027, Balaxi Pharmaceuticals's revenue reached ₹79.69 crore and profit touched at ₹1.30 crore. As of 20 October 2026, Balaxi Pharmaceuticals’s market capitalization reached at ₹120.13 crores. Shareholding as of 20 October 2026 shows promoters holding 66%, DIIs at 2.6%, and public at 31.4%.
Balaxi Pharmaceuticals Fundamental
Market Cap (in crs)
120.13
Face Value
2
Turnover (in lacs)
4.33
Key Metrics
Balaxi Pharmaceuticals Key Financials
View moreBalaxi Pharmaceuticals Result Highlights
-
Balaxi Pharmaceuticals reported a 5.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 27.3%.
-
Its expenses for the quarter were up by 5.1% QoQ and 48.2% YoY.
-
The net profit increased 16.8% QoQ and decreased 60.6% YoY.
-
The earnings per share (EPS) of Balaxi Pharmaceuticals stood at 1 during Q3FY25.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Balaxi Pharmaceuticals Technical Analysis
Delivery & Volume
Delivery Volume %
Day
74.80%
Week
78.80%
Month
75.80%
Resistance & Support
Balaxi Pharmaceuticals Peer comparison
CompareIndex Name | Market Price |
|---|---|
108.97 -3.95 (-3.50%)▼ | |
208.99 +0.88 (+0.42%)▲ | |
101.30 -4.70 (-4.43%)▼ | |
57.88 -2.31 (-3.84%)▼ | |
31.27 +1.10 (+3.65%)▲ | |
103.00 -2.95 (-2.78%)▼ |
Balaxi Pharmaceuticals Share Price FAQs
Balaxi Pharmaceuticals Ltd share price in the past 1-year return was -47.08. The Balaxi Pharmaceuticals Ltd share hit a 1-year low of Rs. 15.2 and a 1-year high of Rs. 43.85.
The market cap of Balaxi Pharmaceuticals Ltd is Rs. 120.13 Cr. as of 19/10/2026.
The PE ratios of Balaxi Pharmaceuticals Ltd is 32.47 as of 19/10/2026.
The PB ratios of Balaxi Pharmaceuticals Ltd is 0.9 as of 19/10/2026
You can easily buy Balaxi Pharmaceuticals Ltd shares in Kotak Neo by opening a demat account and getting the KYC documents verified online.
The 52-week high and low of Balaxi Pharmaceuticals Ltd share price is ₹43.85 and ₹15.2 as of 19/10/2026.
Please be aware that Balaxi Pharmaceuticals Ltd stock prices are subject to continuous fluctuations due to various factors.